REGENXBIO Inc.
RGNX · XNASCIK 1590877fmd_177W0WSHK65PBBHWF7XJ3HM2HVManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 52 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 5 | 10 | 219 | 35 | 155 | 470 | 113 | 90 | 83 | 170 |
| Cost of revenue | 0 | 2 | 10 | 8 | 36 | 52 | 55 | 37 | 34 | – |
| Gross profit | 4 | 9 | 209 | 27 | 119 | 419 | 58 | 53 | 50 | – |
| Realized investment gains (losses) | – | – | – | 38 | 5 | 5 | (0) | 2 | 7 | 0 |
| Provision for credit losses | – | – | – | – | – | – | – | – | (5) | – |
| Research and development | 45 | 57 | 84 | 124 | 166 | 181 | 242 | 232 | 209 | 228 |
| Operating income | (65) | (76) | 88 | (149) | (119) | 160 | (263) | (268) | (233) | (161) |
| Interest expense | – | – | – | – | 1 | 26 | 23 | 7 | 13 | 45 |
| Interest and investment income | – | – | – | – | – | – | 6 | 9 | 12 | 12 |
| Other non-operating income (expense) | 2 | 3 | 16 | 52 | 13 | (19) | (18) | 4 | 6 | (33) |
| Income before taxes | (63) | (73) | 104 | (97) | (106) | 141 | (280) | (264) | (227) | (194) |
| Income tax expense | (0) | 0 | 4 | (3) | 5 | 13 | (0) | (0) | 0 | 0 |
| Net income from continuing operations | (63) | (73) | 100 | (95) | (111) | 128 | (280) | (263) | (227) | (194) |
| Net income | (63) | (73) | 100 | (95) | (111) | 128 | (280) | (263) | (227) | (194) |
| Net income to common shareholders | (63) | (73) | 100 | (95) | (111) | 128 | (280) | (263) | – | – |